Rossari Biotech's subsidiary, Unitop Chemicals, has sold its office premises on May 21, 2026, for INR 10.5 crores as part of the standard third-party sales agreement, including applicable stamp duties.

Rossari Biotech's FY26 revenue rose by 15% to ₹2,396 crore, primarily driven by increased exports, strategic capacity expansions, and growth in their pharmaceutical, agricultural, and oil & gas sectors. The company also recorded an EBITDA of ₹286 crore, indicating an 8% YoY growth.

Rossari Biotech reported a significant 34% year-over-year increase in Q4 net profit, reaching ₹460 million, while Q4 revenue surged by 21% YoY to ₹7 billion.

Rossari Biotech reported a strong Q4 with revenue of INR 684.9 crore and EBITDA of INR 77.3 crore, marking a 15.2% year-on-year increase in revenue for FY26 to INR 2396.4 crore, while profit after tax grew by 9.4% YoY to INR 286 crore.

Rossari Biotech has shifted its Research & Development operations to Navi Mumbai, marking a strategic move for the company's ongoing research activities. It's important to note that this decision was made independently and no involvement from Business Standard journalists was reported in the announcement.

Rossari Biotech announces a 25% final dividend for shareholders, while also releasing their FY26 audited results. A new independent director has been appointed, and the capacity expansion plan has been rescheduled. Additionally, they've established a new R&D facility.

Rossari Biotech's Q4 profits surged by 33.4%, reaching INR 46 crore, driven by an 18.2% increase in revenue to INR 684.8 crore. The company announced a 25% dividend distribution and plans for phased capacity expansion, along with the opening of a new R&D facility in Navi Mumbai.

Rossari Biotech has delayed its planned capacity expansion for at least two years, indicating an adaptive approach to the present market challenges. This move is aimed at maintaining strategic objectives.

Unitop Chemicals, a subsidiary of Rossari Biotech, has recently commissioned an ethoxylation capacity expansion of 15,000 MTPA, reaching halfway to their planned 30,000 MTPA expansion goal. By March 2026, Rossari Biotech's total manufacturing capacity will increase to 66,000 MTPA.